Hematology Special Issue (October)

Actress Marlee Matlin shares her strategy for weathering health challenges, including her father's myeloma diagnosis.

A lone dynamo has raised a million dollars for myeloma research through amazing athletic endeavors, such as running 200 miles nonstop.

Anticoagulants can reduce a heightened risk of blood clots in cancer patients.

By taking the brakes off immune response, immunotherapy empowers the body to fight resistant or recurrent classical Hodgkin lymphoma.

There’s an enormous — and growing — menu of treatments for B cell lymphomas.

With its series of hikes, Moving Mountains for Multiple Myeloma inspires donations — and pride.

Targeted drugs known as TKIs have improved the prognosis for patients with chronic myeloid leukemia.

IN THIS SPECIAL ISSUE of CURE®, among other highlights in the treatment of blood cancers, we detail yet another example of a new application for immunotherapy, this time focusing on the use of PD-1 (checkpoint) immunotherapy to treat Hodgkin lymphoma.

IT’S NOT OFTEN that we hear the terms “good news” and“cancer” in the same sentence. But this special issue of CURE® does bring good news — reports of a series of exciting breakthroughs in the blood cancer arena that are significantly improving treatment options for patients.